Every 8-K that Labcorp Holdings Inc. (LH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LH filings page.
Labcorp Holdings Inc. (LH) hosted its 2026 Investor Day, reaffirming full-year 2026 guidance and providing a detailed long-term outlook through 2029. For 2026, Labcorp continues to target enterprise revenue of $14.71–$14.83 billion, implying 5.4%–6.3% growth versus 2025, driven by Diagnostics Laboratories revenue of $11.45–$11.53 billion and Biopharma Laboratory Services revenue of $3.27–$3.30 billion. Adjusted EPS guidance remains $18.10–$18.55, up 10.1%–12.8% year over year, with free cash flow of $1.24–$1.36 billion. Labcorp also reiterated its 2026–2029 long-term framework of 5%–8% compound annual revenue growth, 8.5%–11.5% compound annual adjusted EPS growth, adjusted operating margin expansion of 75–150 basis points by 2029, and free cash flow growth in line with adjusted earnings, supported by technology-enabled efficiency programs and disciplined capital deployment.
Labcorp Holdings Inc. (LH) announced that members of its executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 11:30 a.m. ET. A live audio webcast will be accessible through Labcorp’s investor relations website and archived for 180 days.
Labcorp describes itself as a global provider of innovative and comprehensive laboratory services, with nearly 71,000 employees serving clients in about 100 countries, supporting more than 85% of new drugs and therapeutic products approved by the FDA in 2025 and performing over 750 million tests annually.
Labcorp Holdings Inc. (NYSE: LH) reported that it will host an Investor Day on September 10, 2026, from 9 a.m. to noon ET. Chairman and CEO Adam Schechter, CFO Julia Wang and other executives plan to present the company’s go-forward strategy, capital deployment priorities and long-term financial outlook, followed by a Q&A session. A live webcast and subsequent replay with supporting materials will be available via the company’s investor relations website.
Labcorp describes itself as a global leader in laboratory services with nearly 71,000 employees serving clients in approximately 100 countries. It supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients worldwide.
Labcorp Holdings Inc. reports a leadership change in its laboratory services business. On August 11, 2026, Megan D. Bailey notified the company of her decision to resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026.
Effective September 1, 2026, Brian J. Caveney, M.D., currently Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer. In this expanded role, he will oversee both the Early Development Research Laboratories and Central Laboratories businesses.
Labcorp Holdings Inc. reported strong results for the quarter ended June 30, 2026, with revenue of $3.73 billion, up 5.8% year over year, and diluted EPS of $3.64 versus $2.84. Adjusted EPS rose to $4.99, and adjusted operating margin improved to 15.8%.
Diagnostics Laboratories and Biopharma Laboratory Services both delivered mid‑single‑digit revenue growth and higher adjusted operating margins. Biopharma Laboratory Services revenue was $836.2 million, up 6.5%, and backlog was $8.73 billion, with a trailing twelve‑month book‑to‑bill of 1.03.
Labcorp raised its 2026 outlook, guiding to enterprise revenue of $14,710–$14,827 million and adjusted EPS of $18.10–$18.55. During the quarter it invested $225.7 million in acquisitions, repurchased $353.8 million of stock, paid $58.7 million in dividends, retired $500.0 million of senior notes, and its board increased the remaining share repurchase authorization to $1.4 billion.
Labcorp Holdings Inc. reported that its Board of Directors declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on September 11, 2026 to stockholders of record at the close of business on August 28, 2026.
Labcorp describes itself as a global leader in innovative and comprehensive laboratory services, supporting doctors, hospitals, pharmaceutical companies, researchers, and patients. The company has nearly 71,000 employees, serves clients in approximately 100 countries, supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients worldwide.
Labcorp Holdings Inc. will release its financial results for the second quarter of 2026 before the market opens on July 30, 2026. The company will host a webcast at 9:00 a.m. ET the same day to discuss the results.
The earnings press release and detailed financial information will be posted in the “News & Events” section of Labcorp’s investor relations website, where investors can also access the live webcast link. A replay of the webcast will be available on the same site about two hours after the live event and will remain accessible for one year.
Labcorp Holdings Inc. will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET. The session will be available via live webcast on the Labcorp Investor Relations website, with an archived recording accessible for 90 days.
The company highlights its global scale, with nearly 71,000 employees serving clients in about 100 countries. Labcorp supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025 and performed over 750 million tests for patients worldwide.
Labcorp Holdings Inc. reported final voting results from its 2026 Annual Meeting of Shareholders. As of the March 26, 2026 record date, 82,187,046 common shares were outstanding, and 76,382,627 shares were represented in person or by proxy, constituting a quorum.
Shareholders elected all nominated directors to serve until the 2027 annual meeting or until their successors are qualified. They also approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers.
In addition, shareholders ratified the appointment of Deloitte & Touche LLP as Labcorp’s independent registered public accounting firm for the year ending December 31, 2026.
Labcorp Holdings reported solid growth for the first quarter ended March 31, 2026 and raised its full‑year 2026 outlook. Revenue reached $3.54 billion, up 5.8% from $3.35 billion a year ago, driven by both Diagnostics Laboratories and Biopharma Laboratory Services.
Diluted EPS rose to $3.35 from $2.52, while Adjusted EPS increased 10.6% to $4.25. Operating income improved to $380.8 million and adjusted operating margin expanded to 14.4% from 14.0%. Free cash flow swung to $70.5 million from negative $107.5 million, helped by higher cash earnings.
Diagnostics revenue grew 5.0% to $2.76 billion with adjusted margin of 16.6%, and Biopharma revenue grew 8.2% to $780.6 million with a 15.5% adjusted margin. Labcorp invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid $61.2 million in dividends.
For 2026, the company now targets enterprise revenue of $14.65–$14.80 billion (5.0–6.1% growth) and Adjusted EPS of $17.70–$18.35, modestly above its prior ranges.
Labcorp Holdings Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend will be paid on June 11, 2026 to stockholders who are on record at the close of business on May 29, 2026.
The company highlights its global scale, noting nearly 71,000 employees serving clients in about 100 countries and performing more than 750 million tests annually, as well as providing support for 85% of new drugs and therapeutic products approved by the FDA in 2025.
Labcorp Holdings Inc. will release its financial results for the first quarter of 2026 before the market opens on Thursday, April 30, 2026, and will host a conference call and webcast at 9:00 a.m. ET to discuss the results.
The earnings press release and financial information will be posted on the Labcorp Investor Relations website, where a link to the webcast and a replay available for one year will also be provided. Labcorp is described as a global leader in laboratory services, with nearly 71,000 employees serving clients in about 100 countries.
Labcorp Holdings Inc. entered into a new Credit Agreement providing a $750,000,000 senior unsecured term loan maturing on March 20, 2028. The loan was fully funded at closing and bears floating interest at either a SOFR-based rate plus a 0.700% margin or a base rate plus a 0% margin.
The agreement includes customary covenants limiting additional subsidiary debt, liens, mergers, and major asset sales, along with standard events of default. It also requires Labcorp to maintain a consolidated leverage ratio not exceeding 4.0 to 1.0, with the ability to increase this to 4.5 to 1.0 for four quarters in connection with a material acquisition under a defined “Leverage Holiday” framework.
Labcorp Holdings Inc. reported solid growth for 2025 and issued an upbeat 2026 outlook. Revenue rose to $13.95 billion from $13.01 billion, while diluted EPS increased to $10.46 from $8.84 and adjusted EPS climbed to $16.44 from $14.57. Free cash flow improved to $1.21 billion from $1.10 billion.
In the fourth quarter, revenue reached $3.52 billion with adjusted EPS of $4.07, supported by margin expansion in Diagnostics and Biopharma Laboratory Services. For 2026, Labcorp guides to enterprise revenue growth of 4.7%–6.0%, adjusted EPS of $17.55–$18.25, and free cash flow of $1.24–$1.36 billion. The company invested heavily in acquisitions, new specialty tests, and a planned 500,000 square foot central lab facility, while returning cash through $0.72 per-share dividends and $450 million of share repurchases.
Labcorp Holdings Inc. has appointed John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026, and named him to the Board’s Quality and Compliance Committee.
Dr. Sampson is vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine and previously held senior leadership roles at Duke University Health System. He is a nationally recognized neurosurgeon and physician-scientist with nearly 300 peer-reviewed publications and extensive experience in oncology, neuroscience, women’s health and personalized medicine. He will receive board compensation consistent with Labcorp’s existing director compensation program.
Labcorp Holdings Inc. amended its receivables purchase agreement on January 28, 2026, extending the scheduled termination date of its receivables facility to January 26, 2029. The facility continues to provide funding backed by accounts receivable through Labcorp Receivables LLC.
The amendment adds a committed $125 million accordion feature, allowing Labcorp Receivables to increase the facility limit from $700 million to up to $825 million at its option on or before May 29, 2026, and removes a prior 0.10% SOFR yield adjustment. Labcorp Receivables remains a separate legal entity whose creditors have first claim on its assets, with excess collections potentially remitted to Labcorp.
Labcorp Holdings Inc. reported that it plans to release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast at 9 a.m. ET that same day to review and discuss the results with investors and analysts. The earnings press release and detailed financial information will be made available on the Labcorp Investor Relations website, giving shareholders and other interested parties direct access to the figures and commentary.
Labcorp Holdings Inc. declared a cash dividend of $0.72 per share of common stock. The dividend will be paid on March 12, 2026 to shareholders who are on record as of the close of business on February 27, 2026. This payment reflects the company’s ongoing practice of returning cash to its stockholders through regular dividends.
Labcorp Holdings Inc. reported that it will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference. The session is scheduled for Tuesday, January 13 at 4:30 p.m. (PT) and will feature company representatives discussing Labcorp’s business with investors and industry participants.
The company will provide a live audio webcast of the fireside chat through its investor relations website at ir.Labcorp.com, and the recording will be archived for replay. Labcorp also furnished a press release dated December 30, 2025 as an exhibit, formally announcing its conference participation.
Labcorp Holdings Inc. reports that Mark Schroeder, its Executive Vice President, President, Diagnostics Laboratories and Chief Operations Officer, has notified the company of his intention to retire.
His retirement is expected to be effective on April 1, 2026, giving the company time to manage the transition of responsibilities across its diagnostics laboratories operations and broader executive team.
Labcorp Holdings Inc. reported that board member Dr. D. Gary Gilliland has decided to retire from its Board of Directors. The company received his notice on December 5, 2025, and his retirement will be effective December 31, 2025. Labcorp later issued a press release on December 10, 2025 to publicly announce his upcoming departure, and that release is included as an exhibit to this report.
Labcorp Holdings Inc. reported that its Board of Directors has appointed Victor Bulto as a new board member, effective December 1, 2025. He will receive director compensation consistent with Labcorp’s existing director compensation program described in its most recent proxy statement.
Bulto is President of Novartis U.S. and a member of the Novartis Executive Committee, roles he has held since April 2022. Over more than two decades at Novartis, he has led major therapeutic franchises and regional businesses, including U.S. Pharmaceuticals and European neuroscience. Labcorp later issued a press release announcing his appointment and filed it as an exhibit, highlighting his extensive pharmaceutical and leadership background.
Labcorp Holdings Inc. filed a current report to furnish a press release announcing its 2025 third quarter results. The filing identifies a press release dated October 28, 2025, titled “Labcorp Announces 2025 Third Quarter Results” as an exhibit, indicating the company has publicly shared its Q3 2025 performance details through that document.
The company lists its common stock, par value $0.10 per share, as trading on the New York Stock Exchange under the symbol LH. The report is signed on behalf of Labcorp by Executive Vice President and Chief Legal Officer Sandra D. van der Vaart.
Labcorp Holdings Inc. reported that its Board of Directors has declared a cash dividend of $0.72 per share on its common stock. The dividend will be paid on December 11, 2025 to shareholders who are on record as of the close of business on November 26, 2025. The company described this decision in a press release that is attached as an exhibit to the report.
Labcorp Holdings Inc. announced that it will release its third-quarter 2025 financial results before the market opens on Tuesday, October 28, 2025. The company will host a conference call and webcast at 9 a.m. ET the same day to discuss the results, and the earnings press release with related financial information will be posted on the Labcorp Investor Relations website.
The announcement is furnished through a press release dated September 25, 2025, which is included as Exhibit 99.1 to this report and incorporated by reference.
Labcorp Holdings Inc. announced that members of its executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The session is scheduled for Tuesday, September 9, at 7:45 a.m. ET and will focus on the company’s role as a global provider of innovative and comprehensive laboratory services.
A live audio webcast of the discussion will be available through Labcorp’s investor relations website at ir.Labcorp.com, and the recording will be archived for replay. The company furnished a related press release as Exhibit 99.1 to this report.
Labcorp (NYSE: LH) entered into a $1.0 billion senior unsecured revolving credit facility that replaces its 2021 agreement and pushes final maturity from April 2026 to June 27 2030. The Fourth Amended and Restated Credit Agreement, led by Bank of America, also adds a $500 million accordion, a $100 million swingline, and a $150 million L/C sub-limit.
Pricing is floating: (i) SOFR + 0.805%–1.300% or (ii) base rate + 0–0.300%, plus a facility fee of 0.070%–0.200%, all tiered to long-term debt ratings. Key covenant requires a net leverage ratio ≤ 4.0×, expandable to 4.5× for four quarters following material acquisitions (unlimited leverage-holiday elections subject to reset conditions). As of closing, no amounts are drawn. The agreement contains customary reps, covenants, and default provisions.
Labcorp Holdings (NYSE: LH) filed a Form 8-K disclosing that it will release its second-quarter 2025 financial results before market open on Thursday, July 24, 2025. Management will host a conference call and webcast at 9 a.m. ET the same day. The filing contains no preliminary results, strategic updates or other material information.